Editor, Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social
Co-Editor, Clinical Medicine Insights: Oncology | Rare Tumors
Lingling Tian
Loading...
🧪 New study protocol published!
TROPION-Lung14 (phase III) evaluates osimertinib + datopotamab deruxtecan vs osimertinib alone in 1L EGFR-mutated advanced NSCLC.
Could combination therapy reshape first-line treatment?
🔗 Read more: buff.ly/pp3eAk2
#Oncology #LungCancer #NSCLC #ClinicalTrials #EGFR
📊 New real-world evidence:How do apalutamide and enzalutamide compare for PSA response in metastatic castration-sensitive prostate cancer?
This study provides important comparative insights to inform treatment decisions.
🔗 Read now: buff.ly/CsFU3XV
#ProstateCancer #Oncology #RealWorldEvidence #mCSPC
Precision approaches have reshaped AML care, yet relapse and resistance remain major challenges. This Collection seeks clinically grounded and translational work addressing MRD, molecular risk, immune strategies, and treatment sequencing across #AML.
Deadline: 19 Feb 2027
buff.ly/xsqkygl
Using spatial profiling, scRNA‑seq, and transcriptomic meta‑analysis, this study links S100A4⁺ antigen‑presenting CAFs with immune‑rich niches and complete resection outcomes in relapsed ovarian cancer.
buff.ly/hL0LhWe
#OvarianCancer #TumorMicroenvironment #CAFs
🆕 New - Does timing matter in radiotherapy?
This study shows that time‑of‑day radiotherapy influences radiation pneumonitis risk, but not survival, in #lungcancer patients with #ILD
🔗 buff.ly/vvUviVC
#Radiotherapy #CancerToxicity #Oncology
🧠📣 New Special Collection in Ther Adv Med Oncol: #ADCs in Gynecologic Cancers. We invite clinically focused work on ADC targets, sequencing, toxicity, and combinations in ovarian, endometrial, and cervical cancers.
🗓️ Deadline: 26 Feb 2027
buff.ly/30K8r13
#GyneOnc #CancerTrials
🧬 New review:
What are the current standards, and what’s next, for platinum-refractory male germ cell cancers? This article explores evolving strategies and future directions in a challenging treatment landscape.
🔗 Read more: buff.ly/QqtRKue
#Oncology #GermCellTumors #CancerResearch #Urology
📊 Antibody–drug conjugates outperform chemotherapy in EGFR-TKI-resistant NSCLC, according to this Bayesian network meta-analysis.
What does this mean for post-TKI treatment strategies?
🔗 Read now: buff.ly/mBdISSD
#Oncology #NSCLC #LungCancer #ADCs #CancerResearch
In resected #AcralMelanoma, this multicenter retrospective study found adjuvant anti‑PD‑1 therapy achieved RFS comparable to high‑dose interferon, with substantially fewer grade 3–4 toxicities. KIT‑mutant disease showed a signal of greater benefit. Ther Adv Med Oncol
buff.ly/QukRAI9
#Immunotherapy
📣 Call for Papers: Advances in Targeted Therapeutics for Pancreatic Cancer: Redefining Precision Oncology in the KRAS Era
✅ Open now | 📅 Deadline Mar 1, 2027
KRAS targeting, resistance, combinations, beyond KRAS & advanced models.
🔗 buff.ly/eMwzb2N
#PancreaticCancer #KRAS #Oncology #CallForPapers
